Introduction. Anti-inflammatory, separate from anti-thrombotic activity of low molecular weight heparin, is still not well documented.
tion of non-specific mediators like C-reactive proteins [6] . Anti-coagulant properties of heparin are well known, but its anti-inflammatory effects are not well documented. Potential mechanisms by which heparin can exert its anti-inflammatory activity are still discussed [7] . Anti-inflammatory properties of heparin are considered to be a result of its ability to bind and inhibit the activity of inflammatory mediators as well as directly inhibiting of inflammatory cells activity [8] .The pro-inflammatory cytokine: TNF-alpha is one of the main mediators of cell-mediated lung injury in COPD [9] . The anti-inflammatory cytokine: IL-12 is secreted by peripheral lymphocytes after induction. The most powerful inducers of IL-12 secretion are bacteria and bacterial products. IL-12 appears to bind to heparin with particularly high affinity [10] .
IntRoduCtIon
Chronic obstructive pulmonary disease (COPD) represents an increasing epidemiological problem throughout the world. Exacerbations of COPD cause high number of hospital admissions, morbidity, mortality and influence on health-related quality of live [1, 2] . There is urgent need of novel therapeutic options to modify inflammation during COPD [3] . Exacerbations of COPD is associated with local and systemic inflammatory response with elevated levels of circulating inflammatory cytokines and acute phase proteins [4, 5] .
The course of inflammation in COPD exacerbation is determined by the balance between pro-inflammatory and anti-inflammatory mediators including tumor necrosis factor alpha (TNF-alpha) and interleukin-12 (IL-12) and activadoI: 10.2478/pjph-2014-0010 In the recent study, we investigated an influence of enoxaparin on serum levels of TNF-alpha and IL-12, in COPD exacerbations, in humans. C-reactive proteins (CRP) serum levels were also estimated simultaneously.
AIM
We estimated an influence of enoxaparin on serum levels of tumor necrosis factor alpha, as the pro-inflammatory cytokine and interleukin-12, as the heparin-binding, antiinflammatory cytokine, in exacerbations of chronic obstructive pulmonary disease, in humans.
MAtERIAL And MEtHodS
We enrolled to the study 73 patients (48 males, 25 females) aged 56-75 years, with COPD exacerbations. The study was approved by an institutional review board bound by the Declaration of Helsinki [11] . All patients were volunteers and each person had written and signed patient's informed consent before entering the study. To participate in the study, patients needed to have moderate to severe COPD, based on the Global Obstructive Lung Disease scale [12] . Patients with very severe COPD exacerbations, with respiratory failure requiring intubation, and severe organ failure, were excluded from the study.
Seventy-three consecutive patients with COPD exacerbation were randomized into two groups: heparin-recipients (37 persons) and heparin non-recipients (36 persons). Concomitant medications included intravenous administration of antibiotics, according to sensitivity of pathogens obtained from sputum smear, theophylline in proper doses per kg of body mass, inhaled short and long-acting beta-mimetics, inhaled anti-cholinergic drugs in stable doses during the all study period. Heparin-recipients received 40 mg enoxaparin in once daily dose, subcutaneously. The duration of study was 14 days. Serum samples were obtained from both study groups and collected just before initiating treatment and after 7 and 14 days of treatment. Serum concentrations of TNFalpha were determined by ELISA kit (Genzyme Diagnostics, Cambridge) with minimal detection limit 5 pg/ml and curve range from zero to 500 pg/ml and lower limit sensitivity at 10 pg/ml. Serum levels of IL-12 were measured by ELISA kit (Genzyme Diagnostics, GBL) with the lower limit sensitivity of the assay: 20 pg/ml. C-reactive proteins serum levels were measured by C-Reactive Protein ELISA kit with lower limit sensitivity 10 pg/ml. All serum samples were randomly assigned code numbers and assayed in a single batch without the knowledge of the clinical status of patient or stage of treatment (heparin recipients or non-recipients). The data obtained from the study were expressed as the mean values with standard deviation. Statistical differences between two study groups were described by Student's t-test with the fiducially limit being p=0.05. Serial changes of TNF-alpha, IL-12 and CRP serum levels were examined by analysis of variance and any significance was further sought by least significance difference. Repeated measures analysis of variance test was used to compare serum levels of IL-12, TNFalpha and CRP with baseline values just before treatment and after 7 and 14 days of treatment, within each study group and between two study groups (enoxaparin-recipients and enoxaparin non-recipients) in each study period.
RESuLtS
In both study groups we observed statistically significant gradual decreasing of TNF-alpha serum levels during all the study period, to compare period before treatment initiation: 168.33 pg/ml (p<0.01; SD +/-2.78). This gradual decline was significantly deeper in heparin recipients (98.62 pg/ml after 7 days and 85.67 pg/ml after 14 days of treatment) to compare heparin non-recipients (126.33 pg/ml after 7 days and 102.82 pg/ml after 14 days of study), p<0.05. These results are illustrated on Figure 1 . IL-12 serum levels were significantly higher in heparin-recipients both after 7 days of treatment (67.46 pg/ml, SD +/-3.30 pg/ml) and 14 days of treatment (89.32 pg/ml, SD +/-3.8) to compare heparin non-recipients (52.32 pg/ml, SD +/-2.35) after 7 days of treatment and after 14 days of treatment (58.44 pg/ml, SD +/-3.35), p<0.05. These results are illustrated on Figure 2 . CRP serum levels were significantly higher in enoxaparin non-recipients to compare enoxaparin non-recipients in each study period (p<0.05). After 14 days of treatment significant deep decline of CRP serum level in heparinrecipients (45.136 pg/ml, SD +/-3.52) to compare the day
